Clinical Trial Update: A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating the combined use of tocilizumab and flupentixol-melitracen for Thyroid-Associated Ophthalmopathy, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid-associated Ophthalmopathy

Drugs mentioned

• Flupentixol-Melitracen (Flupentixol; Melitracen)
• Tocilizumab (tocilizumab)

Snippet

Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Conditions: Thyroid-Associated Ophthalmopathy | Phase 4 | Status: RECRUITING